Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of the world’s leading labs.
Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Our expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today our focus is on HIV but our methods and expertise can be applied to other viruses.
Cavidi’s head office is in Uppsala, Sweden and we have sales offices in South Africa, India and USA. Our customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.
Cavidi is ISO13485 certified for quality management systems.>> Download the Corporate Cavidi Brochure
Board of Directors
Erik Walldén, Chairman,
Chairman and President of Wallden Associates, business consultancy within the field of biotechnology
Mr. Walldén has more than 30 years of experience as executive manager with a record of achievements in the biotech and life science industry Between 2009 and 2013 he has served as President and CEO of Gyros AB, which he has taken from a proof of concept for nano-scale immunoassays and microfluidic lab automation to an established standard analytical platform in the international industry for the development of protein based therapeutics. Before that he served as President and CEO of Affibody Holding AB, which he left in December 2008 after having concluded a restructuring of the company to sustainable profitability. Prior to this he was the President and CEO of Biacore International AB (BCOR:SSE) which after a succesful turnaround was sold to GE Healthcare in 2006. Earlier Mr. Walldén led, as President and CEO, the development of Pyrosequencing AB (now Biotage AB) from venture financed start up through a successful IPO on OMX Stockholm in 2000. He has also been instrumental in establishing and growing companies such as PerSeptive Biosystems, Inc. (now part of Life Technologies, Inc.), Pharmacia biosensor AB (now part of GE Healtcare Lifesciences), and Pharmacia Biotech (now GE Healthcare Lifesciences)He currently serves on the board of directors of Virgin Instruments Corporation, Inc, Beactica AB and CellSeed AB, and previously, on the Industrial Supervisory Board of Healtinvest Partners AB, the board of directors of Exiqon A/S, Tecan Group Ltd and Genovis AB. Specialties: International marketing and sales in the life science and biotechnology markets;Commercialization of new technologies;Strategic turn arounds and restructuring of global organizations;Executive management through equity financing processes, IPO's and M&A transactions.
Fredrik Strömholm, Partner at Impilo
Fredrik Strömholm joined Impilo in 2016 and is chairman of the Impilo investment committee. Fredrik graduated with an M.Sc. in Economics from the Stockholm School of Economics in 1989, with a major in finance from the Ecole des Hautes Etudes Commerciales in France. Fredrik has also studied French, Russian and East European history at the universities of Uppsala and Stockholm. Fredrik is also a graduate of the Swedish Army Language School. Prior to founding Impilo, Fredrik was a partner at Altor Equity Partners, a firm he co-founded in 2003. 1989-1996 and 1999-2002 Fredrik worked at Goldman Sachs International, the last period as managing director responsible for corporate finance and M&A execution in the Nordic region. 1996-1999 Fredrik worked as an investment manager at Nordic Capital in Stockholm. Fredrik serves on the boards of directors of Ferrosan Medical Devices, Ampco Pittsburgh and Ortic 3D. He has previously served on the boards of Antula Healthcare, Nycomed, ACO Hud, Ferrosan, Palodex, Apotek Hjärtat, and Curato within the healthcare sector and on the boards of AGR, Nimbus, Qmatic, Åkers and Carnegie Investment Bank in other industries. Fredrik is the chairman of Natur and Kultur, a foundation with a large publishing business, treasurer of the Academica Foundation and a board member of Skellefteå AIK Ishockey.
Ernst Westman, Professional Board Member, Consultant, & Investor Chalmers University of Technology Stockholm, Stockholm County, Sweden
Former CEO of Boule Diagnostics AB from 1996 - April 1, 2017. Boule Diagnostics AB, Nasdaq Stockholm. He also served as the President of Bactus AB. Experienced Chief Executive Officer with a demonstrated history of working in the medical device industry. Strong business development professional skilled in Research and Development (R&D), Medical Devices, Life Sciences, Business Development, and Venture Capital. Chairman Devyser Stockholm, Sweden, Board Member Astrego Diagnostics AB Stockholm, Sweden, Chairman Capitainer AB, Stockholm Sweden.
Veronica Byfield Sköld, Partner at Impilo
Veronica Byfield Sköld joined Impilo in 2017 and is member of the firm's investment committee. She graduated with an MSc in Industrial Engineering & Business Management from the Royal Institute of Technology in 1999. After her studies, Veronica joined the Boston Consulting Group where she worked between 1999 and 2004. Following BCG, Veronica worked with strategy and business development for Swedish medtech company Gambro (2004-2006), before joining branding and communication agency The Brand Union as Executive Client Director (2006-2009). Turning back to medtech, Veronica then joined Elekta, where she held several Vice President positions in the areas of strategic marketing, commercialization and medical affairs between 2009 and 2016. Before joining Impilo she served on the executive management team of medical device company Permobil as Senior Vice President Group Marketing & Medical Affairs.
Cynthia (Cindy) Collins, CEO, Human Longevity
Cynthia has more than 35 years of experience in leading global teams in diagnostic, life sciences, and biopharma businesses. Most recently she served as the CEO/GM of GE Healthcare’s Cell Therapy and Lab Businesses as well as CEO, Clarient Diagnostics, Inc. Prior to joining GE, she served as President and CEO of GenVec, Inc., a publicly-traded biopharmaceutical company focused on developing gene therapies and vaccines. Prior to that, Ms. Collins served as Group Vice President, Cellular Analysis Business (Coulter) of Beckman Coulter until its sale to Danaher in 2011. Prior to joining Beckman Coulter, Ms. Collins served as President and CEO of Sequoia Pharmaceuticals, Inc., a private biotechnology company developing antiviral drugs for HIV and HCV. Before joining Sequoia Pharmaceuticals, Ms. Collins served as President of Clinical Micro Sensors, Inc., a wholly owned subsidiary of Motorola (now GenMark Diagnostics) where she directed the development and commercialization of molecular diagnostic products and led the eventual strategic divestiture of the division. Before Motorola, she spent over 17 years at Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies . Prior to joining Baxter Healthcare, she worked six years in the Diagnostics Division of Abbott Laboratories. Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, with a specialization in marketing, from The University of Chicago Booth School of Business.
David Summa, Vice President, Partnering Peaxy, Inc.
Massachusetts Institute of Technology, San Francisco Bay Area
With more than 30 years of C-suite and consulting experience, Dave has a track record of making growth happen in the life science, material science, clean tech, and consumer product industries. His skill set was built through 10 years in management in large corporations (Monsanto, P&G), 15 years in consulting (McKinsey, Technology Pathfinders, and now Business Model Innovations, LLC), and 10 years as CEO of three science-based start-ups (Mendel, Acumen, Kinestral). Dave’s experience spans the closing of nine financings, licensing deals worth more than $300 million, M&A deals exceeding $500 million, and the creation of three large joint ventures with Fortune 500 corporate partners. Recent clients include the Bill & Melinda Gates Foundation, Cargill, Digital Power, DSM, the Emir of Qatar, Kiverdi, Mascoma, ScanCafe, Scott’s Lawn & Garden, SnapDNA, Synthetic Genomics, and several venture capital funds including Khosla Ventures, Kleiner Perkins, and Versant Ventures.
Scientific Advisory Committee
Professor John MillsChairman Emeritus, Cavidi AB, SB MD FACP FRACP ARCPA, Association of American Scientists (AAAS), Fellow Infectious Disease Society of America, Member Australasian Society of HIV Medicine, Community service Chair, Research Committee, and Director, Prostate Cancer Foundation of Australia, also Managing Director, TissuPath Pty Ltd, Non-executive Director of GBS Venture Partners P/L and Non-executive Director of Phosphagenics Corp (ASX: POH).
Professor Suzanne CroweAM, Macfarlane Burnet Institute for Medical Research and Public Health: Head, Pathogenesis and Clinical Research Program Centre for Virology, Head of Flow Cytometry Laboratory, Head of Clinical Research Laboratory. Consultant Physician in Infectious Diseases and General Medicine, Alfred Hospital, Melbourne, Professor of Medicine and Infectious Diseases (Personal Chair), Monash University, Melbourne, NHMRC Principal Research Fellow, awarded Member of the Order of Australia (AM) for her service to medical research in HIV/AIDS medicine and infectious diseases.
Dr. Brendan LarderChair RDI Scientific Core Group. Dr Larder is one of the world's leading experts in the fields of HIV drug resistance and pharmacogenomics. He holds a PhD in Virology from Cambridge University. Dr. Larder discovered HIV drug resistance. His seminal work on AZT resistance and its genetic basis published in Science in 1989. Dr. Larder has continued to pioneer understanding in the field, unraveling the genetic basis of resistance to several other HIV drugs and developing many of the laboratory techniques for studying HIV drug resistance, including phenotyping and genotyping methodologies.
Professor Anders SönnerborgAdjunct professor in infectious disease Virology at the Department of Medicine, Karolinska University Hospital, Sweden. Anders focuses on research concerning mechanisms of resistance and failure to improve HIV-specific immunity in HIV treatment. In vitro experiments in model systems combined with experimental analysis of well-defined patient populations.
Associate Professor Johan LennerstrandAssociate professor Section of Virology, Department of Medical Sciences, Uppsala University and University Hospital, Uppsala, Sweden.
Clas KällanderFounder and Director of R&D, CAVIDI AB
Ingvar PeterssonScientific Affairs Manager, CAVIDI AB.
Does Cavidi focus exclusively on resource-limited nations?No. Our goal is to create tests that are universally accessible to both developed and developing nations alike. Within that mandate, we must address the fact that three quarters of the world’s population live in resource-limited settings.
What do all Cavidi products have in common?Many medical tests can only be run in highly advanced medical facilities. Cavidi’s vision is a world where proper medical tests are accessible to anyone who needs them. So we strive to produce state-of-the-art tests with a minimal resource footprint. This approach makes Cavidi tests globally applicable but particularly attractive in settings where resources are limited.
How will Cavidi make medical testing more accessible?At Cavidi we try to develop test solutions that adhere to our ACCESS policy:
- Affordable in the context of resource-limited settings
- Clinically relevant to both the diseases and measurement parameters needed
- Comparable to similar tests used in developed nations with regard to accuracy and reliability
- Easy to run and read in the field
- Swifter at showing results
- Suited to the infrastructure-limitations of resource-limited settings